Drugs / TVI-Brain-1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01290692 | Jun 2011 → Dec 2013 | glioblastoma | TVAX Biomedical | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05685004 | Dec 2023 → Nov 2030 expected | brain glioblastoma | TVAX Biomedical | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05936216 | — | glioblastoma | TVAX Biomedical | No longer available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TVI-Brain-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01290692 ↗ |
| Action | Deplete | “ability to kill large numbers of the cancer cells” NCT05936216 ↗ |
| Modality | Vaccine | “Subjects receive the first vaccination of TVI-Brain-1” NCT05685004 ↗ |
| Route | Intravenous | “the activated cells will be infused into the patient's bloodstream” NCT01290692 ↗ |